

B.Pharm. (CBCS Pattern) Semester-VII  
**BP704T - Novel Drug Delivery System**

P. Pages : 3

Time : Three Hours



**GUG/W/24/14146**

Max. Marks : 75

- Notes :
1. Illustrate your answers wherever necessary with the help of neat sketches.
  2. All questions are compulsory.

**1. Multiple choice questions.**

**20**

- i) Which of the following is synthetic polymer.
  - a) Dextran
  - b) Hydroxypropyl cellulose
  - c) Poly lactic acid
  - d) Methyl cellulose
- ii) The paracellular route allows the hydrophilic drugs with molecular weight of –
  - a) Less than 500 Da
  - b) 500-1000 Da
  - c) 1000-2000 Da
  - d) More than 2000 Da
- iii) Ideally, the drug should have half-life to be formulated in controlled release dosage
  - a) 1-2 hrs
  - b) 3-4 hrs
  - c) 6-7 hrs
  - d) 9-10 hrs
- iv) Which of the polymer is non-biodegradable.
  - a) Poly (ethylene vinyl acetate)
  - b) Poly (lactic acid)
  - c) Poly (caprolactone)
  - d) Poly (lactic-co-glycolic acid)
- v) Following can be considered as physico-mechanical technique used for microencapsulation.
  - a) Phase Inversion
  - b) Co-extrusion
  - c) Coacervation
  - d) Hot Melt
- vi) The characteristic that is suitable for transdermal drug is –
  - a) Large drug dose
  - b) Drugs with narrow therapeutic index
  - c) Large molecular size
  - d) Drugs which are metabolized in the skin
- vii) Iontophoresis is used in TDDS as
  - a) Physical penetration enhancer
  - b) Drug carrier
  - c) Chemical penetration enhancer
  - d) Polymer matrix
- viii) PEVA stands for –
  - a) Polyethylene vinyl alcohol
  - b) Poly ethylene vinyl acetate
  - c) Propylene vinyl alcohol
  - d) None of the above

- ix) This is not the chemical permeation enhancer
- |                |            |
|----------------|------------|
| a) Fatty acids | b) Alcohol |
| c) Zein        | d) Glycol  |
- x) For a drug to be formulated in to controlled/modified release dosage form its Margin of safety should be –
- |             |                  |
|-------------|------------------|
| a) Very low | b) Very high     |
| c) Normal   | d) None of above |
- xi) In gastroretentive drug delivery system the device may -----
- |                               |                          |
|-------------------------------|--------------------------|
| a) Float on the gastric fluid | b) Settle in the stomach |
| c) Enlarge in the size        | d) All of the above      |
- xii) Humectant used in nasal products.
- |             |                     |
|-------------|---------------------|
| a) Glycerin | b) Sorbitol         |
| c) Mannitol | d) All of the above |
- xiii) Hydrodynamically balanced system consists of -----
- |                 |                      |
|-----------------|----------------------|
| a) HPMC         | b) Polymethacrylates |
| c) Alginic acid | d) All of the above  |
- xiv) Major components of Niosomes preparation.
- |                |                          |
|----------------|--------------------------|
| a) Cholesterol | b) Non-ionic surfactants |
| c) Both a & b  | d) Ionic surfactants     |
- xv) Monoclonal antibodies have –
- |                         |                      |
|-------------------------|----------------------|
| a) Monovalent affinity  | b) Divalent affinity |
| c) Multivalent affinity | d) All of the above  |
- xvi) Liposomes have ----- half-life.
- |                 |               |
|-----------------|---------------|
| a) Longer       | b) Shorter    |
| c) Intermediate | d) Both a & b |
- xvii) Hormone present in IUDDS is –
- |                    |               |
|--------------------|---------------|
| a) Testosterone    | b) Progestine |
| c) Corticosteroids | d) LH         |
- xviii) The normal volume of tear fluid in the Cul-de-sac region of human eye is -----
- |             |                  |
|-------------|------------------|
| a) 7-8 ml   | b) 7-8 $\mu$ l   |
| c) 12-17 ml | d) 17-18 $\mu$ l |
- xix) Copper containing IUDs causes –
- |                         |                           |
|-------------------------|---------------------------|
| a) Lysosomal activation | b) Lysosomal inactivation |
| c) Fertilization        | d) None of the above      |
- xx) Components of Targeted Drug delivery systems are -----
- |                          |                     |
|--------------------------|---------------------|
| a) Drug carrier          | b) Target           |
| c) Drug delivery vehicle | d) all of the above |

- 2. Solve any two.** **10x2  
=20**
- a) Enlist various approaches to design-controlled release formulations and explain in detail diffusion and dissolution-controlled release system.
  - b) Define microencapsulation, enlist various techniques of microencapsulation and explain any two.
  - c) Define and classify liposomes and explain various methods of preparation of liposomes.
- 3. Solve any seven.** **5x7  
=35**
- a) Discuss the theories of mucoadhesion.
  - b) Write a note on osmotic pressure powdered pump.
  - c) Explain about the basic components used for TDDS.
  - d) Write a note on Niosomes.
  - e) What are intrauterine devices (IUDs) ? Discuss hormone releasing IUDs.
  - f) Explain types, advantages and disadvantages of Ocuserts.
  - g) Discuss about Gastroretentive floating drug delivery systems.
  - h) Write a note on Nebulizers and nasal sprays.
  - i) What are monoclonal antibodies. Write their advantages, limitations and applications.

\*\*\*\*\*

